Cargando…

FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal tumor types worldwide. BET inhibitors display anti-tumor activity in pancreatic cancer, however the cells often develop resistance after a long-term treatment and the underlying molecular basis is not fully understood. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bo, Fan, Ping, Zhao, Jingyuan, Wu, Heyu, Jin, Xin, Wu, Heshui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131902/ https://www.ncbi.nlm.nih.gov/pubmed/30201002 http://dx.doi.org/10.1186/s13046-018-0888-y

Ejemplares similares

Deubiquitination of FBP1 by USP7 blocks FBP1–DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors
por: Cheng, Xiang, et al.
Publicado: (2021)

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2018)

Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2023)

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
por: Miller, Aubrey L., et al.
Publicado: (2019)

The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer
por: Weber, Achim, et al.
Publicado: (2008)

Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway
por: Liu, Zhiqiang, et al.
Publicado: (2020)

Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer
por: Fan, Ping, et al.
Publicado: (2019)

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
por: Farrell, Amy S., et al.
Publicado: (2017)

Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis
por: Meng, Zibo, et al.
Publicado: (2019)

ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma
por: Oria, Victor O., et al.
Publicado: (2019)

B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma
por: Minici, Claudia, et al.
Publicado: (2020)

Pancreatic Ductal Adenocarcinoma at CT: A Combined Nomogram Model to Preoperatively Predict Cancer Stage and Survival Outcome
por: Cen, Chunyuan, et al.
Publicado: (2021)

SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells
por: Chen, Yu-Wen, et al.
Publicado: (2014)

PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
por: Jin, Xin, et al.
Publicado: (2019)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

Clinical-radiomics nomogram using contrast-enhanced CT to predict histological grade and survival in pancreatic ductal adenocarcinoma
por: Cen, Chunyuan, et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Loss of Heterozygosity for Kras(G12D) Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism
por: Ma, Yu, et al.
Publicado: (2022)

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma
por: Tayao, Michael, et al.
Publicado: (2016)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression
por: Liu, Chengmin, et al.
Publicado: (2023)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
por: Sato, Norihiro, et al.
Publicado: (2016)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)

Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma
por: Cole, Jennifer M., et al.
Publicado: (2019)

NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma
por: Ramakrishnan, Gopalakrishnan, et al.
Publicado: (2022)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
por: Sebastian, Aimy, et al.
Publicado: (2023)

Docosahexaenoic Acid Inhibits Cell Proliferation through a Suppression of c-Myc Protein in Pancreatic Ductal Adenocarcinoma Cells
por: Syu, Jia-Ning, et al.
Publicado: (2021)

The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma
por: Shen, Hongzhang, et al.
Publicado: (2021)

Overexpression of rhophilin 2 promotes pancreatic ductal adenocarcinoma
por: Bo, Wentao, et al.
Publicado: (2021)

Apoptotic pathways in pancreatic ductal adenocarcinoma
por: Hamacher, Rainer, et al.
Publicado: (2008)

Pancreaticoduodenectomy of Pancreatic Ductal Adenocarcinoma in the Elderly
por: Kang, Chang Moo, et al.
Publicado: (2007)

Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
por: Ottenhof, Niki A., et al.
Publicado: (2011)

Mast cells in pancreatic ductal adenocarcinoma
por: Chang, David Z.
Publicado: (2012)

Genetics and biology of pancreatic ductal adenocarcinoma
por: Ying, Haoqiang, et al.
Publicado: (2016)

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
por: Li, Junjie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2400slf7mtf9sml6lugeek3lnf